title: Enhanced brain-derived neurotrophic factor signaling in the nucleus accumbens of juvenile rats.
abstract: Brain-derived neurotrophic factor (BDNF) signaling through its receptor, tropomyosin receptor kinase B (TrkB), plays a critical role in neural plasticity and its dysregulation in striatum and prefrontal cortex (PFC) has been implicated in the etiology of mental health disorders such schizophrenia and drug addiction. In the present study, we characterized age-dependent differences in BDNF signaling and TrkB expression within the nucleus accumbens (NAc), caudate putamen (CP) and PFC in rats and determined the effects of administration of the dopamine agonist, SKF 83959, which activates the Gq-coupled dopamine receptors, the dopamine D5 receptor and the D1-D2 receptor heteromer. As proBDNF binds with high affinity to the p75 neurotrophin receptor (p75NTR), expression levels of these proteins were also assessed. The present findings showed that juvenile rats (aged 26-28 days) exhibited significantly elevated basal BDNF expression and activation of full-length TrkB (TrkBfull) in NAc compared to their adult counterparts, as evidenced by increased TrkBfull phosphorylation. These changes were concomitant with an increase in the relative expression of TrkBfull compared to the truncated isoform, TrkB.T1, in NAc and CP. Conversely, in PFC the basal expression of BDNF in juvenile rats was significantly lower than in adult rats with an elevated relative expression of TrkBfull. Acute administration of SKF 83959 to juvenile rats abolished the age-dependent differences in BDNF expression in NAc and PFC, and in the relative expression of TrkBfull in NAc and CP. Together these findings indicate that the expression and/or signaling of BDNF and TrkB in striatum and PFC of juvenile rats is fundamentally different from that of adult rats, a finding that may have implications in neuropsychiatric disorders that exhibit age-dependent susceptibility such as schizophrenia and drug addiction.
authors.affiliation: Centre for Addiction and Mental Health, Departments of Pharmacology, University of Toronto, Toronto, Ont., Canada.
authors.forename: Melissa L
authors.initials: ML
authors.lastname: Perreault
authors.forename: Theresa
authors.initials: T
authors.lastname: Fan
authors.forename: Brian F
authors.initials: BF
authors.lastname: O'Dowd
authors.forename: Susan R
authors.initials: SR
authors.lastname: George
mesh_terms: D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine / Q000031:analogs & derivatives / Q000494:pharmacology; D000367:Age Factors; D000818:Animals; D019208:Brain-Derived Neurotrophic Factor / Q000378:metabolism*; D002421:Caudate Nucleus / Q000187:drug effects / Q000378:metabolism; D018491:Dopamine Agonists / Q000494:pharmacology; D008297:Male; D009474:Neurons / Q000187:drug effects / Q000378:metabolism*; D009714:Nucleus Accumbens / Q000187:drug effects / Q000378:metabolism*; D010766:Phosphorylation / Q000187:drug effects; D017397:Prefrontal Cortex / Q000187:drug effects / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D020800:Receptor, Nerve Growth Factor / Q000378:metabolism; D020813:Receptor, trkB / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology*
chemical_list: D019208:Brain-Derived Neurotrophic Factor; D018491:Dopamine Agonists; D020800:Receptor, Nerve Growth Factor; D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; C080703:SK&F 83959; D020813:Receptor, trkB
references.citation: Proc Natl Acad Sci U S A. 2007 Jan 9;104(2):654-9
references.pmid: 17194762
references.citation: Nature. 1991 Mar 21;350(6315):230-2
references.pmid: 2005978
references.citation: Nat Neurosci. 2005 Aug;8(8):1069-77
references.pmid: 16025106
references.citation: Neuroscientist. 2013 Aug;19(4):345-53
references.pmid: 23242909
references.citation: Psychopharmacology (Berl). 2008 Jan;196(1):71-81
references.pmid: 17922112
references.citation: Eur J Pharmacol. 2010 May 10;633(1-3):1-9
references.pmid: 20149790
references.citation: Am J Psychiatry. 2003 Jun;160(6):1041-52
references.pmid: 12777258
references.citation: Metab Brain Dis. 2012 Jun;27(2):175-82
references.pmid: 22327556
references.citation: Int J Neuropsychopharmacol. 2013 Mar;16(2):477-83
references.pmid: 22827965
references.citation: J Neurosci. 2010 Sep 1;30(35):11735-44
references.pmid: 20810894
references.citation: Neuroscience. 2012 Oct 25;223:219-24
references.pmid: 22890078
references.citation: Neuroreport. 2009 Apr 22;20(6):606-10
references.pmid: 19295451
references.citation: Dev Biol. 1994 Sep;165(1):243-56
references.pmid: 8088442
references.citation: Psychopharmacology (Berl). 1987;92(2):164-8
references.pmid: 3110837
references.citation: J Neurosci. 2005 Jan 12;25(2):372-83
references.pmid: 15647480
references.citation: Neurosci Biobehav Rev. 2000 Jun;24(4):417-63
references.pmid: 10817843
references.citation: J Neurosci. 2005 Jun 1;25(22):5455-63
references.pmid: 15930396
references.citation: Neuroscience. 2003;119(3):767-75
references.pmid: 12809697
references.citation: PLoS One. 2012;7(3):e33348
references.pmid: 22428025
references.citation: Mol Pharmacol. 2009 Apr;75(4):843-54
references.pmid: 19171671
references.citation: Proc Natl Acad Sci U S A. 2009 Dec 15;106(50):21377-82
references.pmid: 19948956
references.citation: Brain Res. 2010 Feb 16;1314:183-93
references.pmid: 19732758
references.citation: Nat Neurosci. 2007 Aug;10(8):1029-37
references.pmid: 17618281
references.citation: Pharmacol Biochem Behav. 2009 Mar;92(1):131-4
references.pmid: 19032962
references.citation: Eur J Neurosci. 1995 Feb 1;7(2):213-22
references.pmid: 7757258
references.citation: Behav Brain Res. 2009 Mar 2;198(1):45-50
references.pmid: 18996417
references.citation: J Neurochem. 2007 Mar;100(6):1515-30
references.pmid: 17286628
references.citation: Nat Med. 2010 Dec;16(12):1393-5
references.pmid: 21113156
references.citation: J Biol Chem. 2004 Aug 20;279(34):35671-8
references.pmid: 15159403
references.citation: Mol Psychiatry. 2013 Oct;18(10):1106-18
references.pmid: 23007167
references.citation: Am J Med Genet B Neuropsychiatr Genet. 2008 Jun 5;147B(4):505-6
references.pmid: 17894414
references.citation: Cytokine Growth Factor Rev. 2012 Feb-Apr;23(1-2):15-24
references.pmid: 22341689
references.citation: J Pharmacol Exp Ther. 1990 Jun;253(3):987-92
references.pmid: 1972756
references.citation: Psychopharmacology (Berl). 2008 Aug;199(2):169-82
references.pmid: 18551281
references.citation: J Neurosci. 2011 Jan 19;31(3):834-42
references.pmid: 21248106
references.citation: Nat Neurosci. 2005 Feb;8(2):164-72
references.pmid: 15665879
references.citation: Eur J Neurosci. 2010 Nov;32(9):1452-60
references.pmid: 20950357
references.citation: Brain Res Dev Brain Res. 1995 Nov 21;89(2):167-72
references.pmid: 8612321
references.citation: J Mol Neurosci. 2011 Mar;43(3):337-45
references.pmid: 20852970
references.citation: Brain Res Bull. 2009 Apr 29;79(2):104-110
references.pmid: 19320060
references.citation: Science. 2001 Nov 30;294(5548):1945-8
references.pmid: 11729324
references.citation: J Neurosci. 2012 Mar 28;32(13):4610-22
references.pmid: 22457507
references.citation: Nat Neurosci. 2000 Apr;3(4):342-9
references.pmid: 10725923
references.citation: Eur J Neurosci. 2007 Aug;26(3):757-66
references.pmid: 17651427
references.citation: J Neurosci. 2008 Mar 5;28(10):2375-82
references.pmid: 18322084
references.citation: Neuropsychobiology. 2007;55(1):2-13
references.pmid: 17556847
references.citation: Behav Brain Res. 2002 Mar 10;130(1-2):197-201
references.pmid: 11864735
references.citation: J Neurochem. 2003 Apr;85(2):378-86
references.pmid: 12675914
references.citation: Synapse. 2000 Aug;37(2):167-9
references.pmid: 10881038
references.citation: J Cell Sci. 2004 Nov 15;117(Pt 24):5803-14
references.pmid: 15507485
references.citation: J Biol Chem. 2010 Nov 19;285(47):36625-34
references.pmid: 20864528
references.citation: Biol Psychiatry. 2009 Apr 15;65(8):696-701
references.pmid: 18990365
references.citation: Neuropharmacology. 2011 Sep;61(3):544-9
references.pmid: 21527264
references.citation: Curr Mol Pharmacol. 2009 Jan;2(1):70-6
references.pmid: 20021447
references.citation: J Neurosci. 1997 Apr 15;17(8):2683-90
references.pmid: 9092589
references.citation: Brain Res. 2007 Jul 2;1156:31-45
references.pmid: 17509542
references.citation: Psychopharmacology (Berl). 2010 Feb;208(2):211-22
references.pmid: 19953228
references.citation: J Neurochem. 1994 May;62(5):2045-8
references.pmid: 7908949
references.citation: J Neurosci. 2007 Jul 4;27(27):7234-44
references.pmid: 17611276
references.citation: Psychoneuroendocrinology. 2012 Jun;37(6):762-72
references.pmid: 21974975
references.citation: Med Hypotheses. 2011 Oct;77(4):508-28
references.pmid: 21741771
references.citation: J Psychiatr Res. 2012 Jan;46(1):1-11
references.pmid: 22030467
references.citation: J Neurosci. 1994 Jan;14(1):335-47
references.pmid: 8283241
references.citation: Brain Res. 2000 Jul 21;871(2):210-22
references.pmid: 10899288
references.citation: Arch Gen Psychiatry. 2003 Aug;60(8):837-44
references.pmid: 12912767
references.citation: Pharmacol Rev. 2012 Apr;64(2):238-58
references.pmid: 22407616
references.citation: Neuroscience. 2012 Dec 6;225:130-9
references.pmid: 22986162
references.citation: Development. 1995 Aug;121(8):2461-70
references.pmid: 7671810
references.citation: Behav Neurosci. 2008 Apr;122(2):460-5
references.pmid: 18410184
references.citation: Lancet. 2007 Mar 31;369(9567):1130-9
references.pmid: 17398312
references.citation: Eur J Pharmacol. 2011 Dec 5;671(1-3):33-8
references.pmid: 21930121
references.citation: Schizophr Res Treatment. 2012;2012:916198
references.pmid: 22966451
references.citation: Nature. 2003 Nov 6;426(6962):74-8
references.pmid: 14603320
references.citation: J Neurosci. 1996 May 15;16(10):3123-9
references.pmid: 8627351
references.citation: Mol Pharmacol. 2009 Mar;75(3):447-53
references.pmid: 19047479
references.citation: J Neurosci. 2009 Mar 25;29(12):3715-9
references.pmid: 19321768